文献速递性腺与生殖内分泌

神经激肽3受体拮抗剂非佐奈坦治疗多囊卵巢综合征的随机对照试验

Randomized Controlled Trial of Neurokinin 3 Receptor Antagonist Fezolinetant for Treatment of Polycystic Ovary Syndrome.
PubMed 文献 · J Clin Endocrinol Metab · 2021-01-01

非佐奈坦耐受良好,可持续抑制高雄激素血症并降低LH/FSH比值。

要点

  • 孕酮和雌二醇水平较安慰剂无显著变化(P>0.10)。

核心结论

  • 非佐奈坦可持续抑制PCOS女性的高雄激素血症并降低LH/FSH比值。

研究设计与样本

  • 2a期随机双盲安慰剂对照多中心研究(EudraCT 2014-004409-34),在5个欧洲临床中心开展。

主要发现

  • 孕酮和雌二醇水平较安慰剂无显著变化(P>0.10),非佐奈坦耐受良好。

关键数值与推荐

  • 主要疗效终点为总睾酮变化,非佐奈坦180和60 mg/日均显著优于安慰剂。

临床怎么用

  • 对于PCOS高雄激素血症患者,非佐奈坦可能作为降低睾酮和LH/FSH比值的候选药物。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

CONTEXT: Polycystic ovary syndrome (PCOS), a highly prevalent endocrine disorder characterized by hyperandrogenism, is the leading cause of anovulatory infertility. OBJECTIVE: This proof-of-concept study evaluated clinical efficacy and safety of the neurokinin 3 (NK3) receptor antagonist fezolinetant in PCOS. METHODS: This was a phase 2a, randomized, double-blind, placebo-controlled, multicenter study (EudraCT 2014-004409-34). The study was conducted at 5 European clinical centers. Women with PCOS participated in the study. Interventions included fezolinetant 60 or 180 mg/day or placebo for 12 weeks. The primary efficacy end point was change in total testosterone. Gonadotropins, ovarian hormones, safety and tolerability were also assessed. RESULTS: Seventy-three women were randomly assigned, and 64 participants completed the study. Adjusted mean (SE) changes in total testosterone from baseline to week 12 for fezolinetant 180 and 60 mg/day were -0.80 (0.13) and -0.39 (0.12) nmol/L vs -0.05 (0.10) nmol/L with placebo (P < .001 and P < .05, respectively). Adjusted mean (SE) changes from baseline in luteinizing hormone (LH) for fezolinetant 180 and 60 mg/d were -10.17 (1.28) and -8.21 (1.18) vs -3.16 (1.04) IU/L with placebo (P < .001 and P = .002); corresponding changes in follicle-stimulating hormone (FSH) were -1.46 (0.32) and -0.92 (0.30) vs -0.57 (0.26) IU/L (P = .03 and P = .38), underpinning a dose-dependent decrease in the LH-to-FSH ratio vs placebo (P < .001). Circulating levels of progesterone and estradiol did not change significantly vs placebo (P > .10). Fezolinetant was well tolerated. CONCLUSION: Fezolinetant had a sustained effect to suppress hyperandrogenism and reduce the LH-to-FSH ratio in women with PCOS.

来源:J Clin Endocrinol Metab,查看原文。版权归原作者所有。

引用

  1. Fraser GL, Obermayer-Pietsch B, Laven J, et al. Randomized Controlled Trial of Neurokinin 3 Receptor Antagonist Fezolinetant for Treatment of Polycystic Ovary Syndrome. J Clin Endocrinol Metab. 2021. PMID: 34000049. doi:10.1210/clinem/dgab320

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。